This section of the website is for patients who have been prescribed Somatuline® Autogel® (lanreotide) in Ireland. Information for members of the general public can be found here.
Side effects reporting information is available at the bottom of this webpage.

The decision to administer the injection by the patient or another trained person should be taken by a healthcare professional

Learning – A part of your guide to Neuroendocrine Tumours (NETs)

Neuroendocrine Tumours (NETs) File
48 pages

This booklet is designed to help patients understand the what, where, who and how of NETs, as well as potential symptoms, tests and treatments associated with NETs.

SOM-IE-000730 | August 2025

Learning – A part of your guide to Neuroendocrine Tumours (NETs)
Explore more Neuroendocrine Tumours (NETs) Patient Support

Explore more Neuroendocrine Tumours (NETs) Patient Support

Browse

To access relevant information about Neuroendocrine Tumours (NETs), please choose one of the following options:

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.